LXEO
Lexeo Therapeutics, Inc. Common Stock
NASDAQ: LXEO · HEALTHCARE · BIOTECHNOLOGY
$5.70
+0.26% today
Updated 2026-04-30
Market cap
$416.74M
P/E ratio
—
P/S ratio
478.26x
EPS (TTM)
$-1.86
Dividend yield
—
52W range
$2 – $11
Volume
0.9M
Lexeo Therapeutics, Inc. Common Stock (LXEO) Financial statements
SEC filings — annual and quarterly data.
Cash flow — annual
| Item | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Operating cash flow | $-3.13M | $-44.18M | $-54.56M | $-59.50M | $-81.15M | $-98.56M |
| Capital expenditures | $0.00 | $188000.00 | $901000.00 | $165000.00 | $481000.00 | $397000.00 |
| Depreciation | $0.00 | $13000.00 | $1.15M | $1.84M | $2.00M | — |
| Stock-based comp | $0.00 | $386000.00 | $1.78M | $3.04M | $12.47M | $12.13M |
| Free cash flow | $-3.13M | $-44.37M | $-55.46M | $-59.66M | $-81.63M | $-98.96M |
| Investing cash flow | — | $-188000.00 | $-901000.00 | $-165000.00 | $-94.08M | — |
| Financing cash flow | $32.38M | $150.86M | $189000.00 | $103.79M | $88.78M | — |
| Dividends paid | — | — | — | — | — | — |
| Share repurchases | — | — | — | — | — | — |
| Debt repayment | — | — | — | — | — | — |
| Net change in cash | — | — | — | — | — | — |